Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook

Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of $0.23, $0.40 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $10.8 million.

Financial Guidance

Cytokinetics also announced its financial guidance for 2015. The company anticipates cash revenue will be in the range of $40 to $43 million, cash R&D expenses will be in the range of $55 to $58 million, and cash G&A expenses will be in the range of $15 to $18 million. This guidance includes approximately $30 million in revenue which will be deferred and recognized over a two year period ending in 2016 under generally accepted accounting principles. This guidance excludes the $15 million milestone payment earned in 2014 from Astellas and an estimated $3.6 million in non-cash related operating expenses primarily related to stock compensation expense.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Green Dot and CommerceOne shareholders approve acquisition deal